Company Pharnext SCA

ALPHA

FR001400N1P4

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:20 2024-04-18 am EDT			5-day change	1st Jan Change
0.1497 ^EUR	-2.79%		-17.75%	-92.52%

Mar. 06	Pharnext: listing suspended pending further update	CF
Feb. 21	Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...

Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.

The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).

Number of employees: 23

EUR in Million	2021	Weight	2022	Weight	Delta
Pharmaceutical Therapies 100.0 %	0	100.0 %	0	100.0 %	-99.34%

EUR in Million	2021	Weight	2022	Weight	Delta
France 100.0 %	0	100.0 %	0	100.0 %	-99.34%

Managers	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	22-11-07
Serguei Nabirotchkine FOU	Founder	-	06-12-31
Melissa Israel CTO	Chief Tech/Sci/R&D Officer	-	20-11-30
Philippe Rinaudo CTO	Chief Tech/Sci/R&D Officer	-	15-11-30
Xavier Paoli COO	Chief Operating Officer	-	14-03-31
Gilbert Wagener CTO	Chief Tech/Sci/R&D Officer	-	23-06-14
Joshua Schafer BRD	Director/Board Member	53	20-06-30
Antoine Gravelle LAW	General Counsel	-	22-06-30
Raj Thota PRN	Corporate Officer/Principal	-	21-10-18
Abhijit Pangu LAW	General Counsel	-	21-10-18

Members of the board	Title	Age	Since
James Kuo BRD	Director/Board Member	58	22-06-15
Lawrence Steinman BRD	Director/Board Member	76	20-07-16
Guy-Charles Fanneau de la Horie BRD	Director/Board Member	64	23-07-09
Hugo Brugière CEO	Chief Executive Officer	-	22-11-07
Joshua Schafer BRD	Director/Board Member	53	20-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	78	77 ( 99.00 %)	0	99.00 %

Pharnext SA

46 rue Saint Lazare

75009, Paris

+33 1 41 09 22 30

http://www.pharnext.com

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
PHARNEXT SCA	-92.52%	28.49K
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals